The IP introduces a significant advancement in cancer immunotherapy by enhancing the efficacy of natural killer (NK) cells in targeting tumors within challenging microenvironments characterized by xenobiotic exposure and hypoxia. This approach involves genetically modifying NK cells to disrupt the aryl hydrocarbon receptor nuclear translocator (ARNT) protein using the Cas9/RNP method. By doing so, it aims to counteract the inhibitory effects of the AhR and HIF1α signaling pathways, thereby augmenting the anti-tumor capabilities of NK cells. The IP holds substantial benefits for cancer treatment. By equipping NK cells with improved resilience against environmental stressors, it offers the potential for more effective and targeted therapeutic interventions, particularly in cases where conventional treatments may prove inadequate. Additionally, the ability to modulate NK cell functionality provides a personalized approach that leverages the innate anti-tumor properties of these cells. There are opportunities for biotechnology and pharmaceutical companies specializing in cancer therapeutics to benefit from the IP, which is currently at the proof of principle stage. The scalability and adaptability of this IP extend its market potential beyond cancer therapy to encompass a broader range of immunological and pathological conditions.